Electron microscopic findings for micafungin-treated experimental pulmonary aspergillosis in mice

Medical Mycology

Volumn 43, Issue 5, 2005, Pages 439-445

  Nakai, Toru ^a   Hatano, Kazuo ^a   Ikeda, Fumiaki ^a   Shibuya, Kazutoshi ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Aspergillus fumigatus; Candin; Electron microscopy; Glucan synthase inhibitor; Pneumonia; Ultrastructure

Indexed keywords

MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ATROPHY; BODY BURDEN; CELL DAMAGE; CELL WALL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL INFECTION; FUNGAL VIRULENCE; FUNGUS HYPHAE; IN VITRO STUDY; LUNG ASPERGILLOSIS; MALE; MOUSE; NONHUMAN; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS; DISEASE MODELS, ANIMAL; LIPOPROTEINS; MICE; PEPTIDES, CYCLIC;

ASPERGILLUS; ASPERGILLUS FUMIGATUS;

EID: 24644456407     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780500057403     Document Type: Article

References (19)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
2. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250-260.
3. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329.
4. Ruhnke M, Eigler A, Tennagen I, et al. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994; 32: 2092-2098.
5. Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs 2001; 10: 269-280.
6. Tomishima M, Ohki H, Yamada A, et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot (Tokyo) 1999; 52: 674-676.
7. Matsumoto S, Wakai Y, Nakai T, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000; 44: 619-621.
8. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57-62.
9. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857-1869.
10. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001-3012.
11. Watabe E, Nakai T, Matsumoto S, Ikeda F, Hatano K. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother 2003; 47: 1995-1998.
12. Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 2001; 45: 3310-3321.
13. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12-23.
14. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42: 2898-2905.
15. Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 1997; 35: 79-86.
16. Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-1489.
17. Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 2002; 51: 247-255.
18. Duong M, Ouellet N, Simard M, et al. Kinetic study of host defense and inflammatory response to Aspergillus in steroid-induced immunosuppressed mice. J Infect Dis 1998; 178: 1472-1482.
19. Watabe E, Nakai T, Matsumoto S, Hatano K, Ikeda F. In vitro pharmacodynamic characterization of micafungin against Aspergillus fumigatus using a fluorescent dye-staining method. In: proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 27 September 2002. Washington, DC: American Society for Microbiology, 2002: A-490.